Conclusions

- At Week 96, both the RAL and EFV regimens demonstrated modest effects on serum lipids and glucose.
- The mean changes from baseline in total cholesterol, LDL-cholesterol, HDL-cholesterol, and triglyceride concentrations were significantly smaller for RAL than for EFV recipients.
- The change in the total cholesterol/HDL-cholesterol ratio was not significantly different between the treatment groups.
- At week 96, DEXA showed small gains in body fat in both treatment groups.
- Longer-term experiences with RAL suggests a favorable metabolic profile associated with minimal changes in body composition in treatment-naive patients.

Acknowledgments

The authors thank all of the patients and partners from the CASTLE Study for their contributions. Additional thanks to the CASTLE Study Investigators, Study Coordinators, and study staff for their contributions to the study. The authors thank the following individuals for their contributions to the analysis: Dr. Matthew Emslie, Dr. Deana Schiano, and Dr. Steven Schuur. The CASTLE Study was funded by Merck & Co., Inc., Rahway, NJ. These authors were employees of Merck & Co., Inc., Rahway, NJ, at the time the study was conducted and during the preparation of this manuscript. The authors are independent scientific investigators and had full access to the data presented in this manuscript. The contents of this manuscript were reviewed by Merck & Co., Inc., Rahway, NJ, prior to submission for this publication. Any views or opinions expressed in this manuscript are those of the authors and do not necessarily represent the views of Merck & Co., Inc., Rahway, NJ or any of its employees. This manuscript was prepared in accordance with the instructions and requirements of the International Committee on Harmonization (ICH) Guidance, Good Clinical Practice (GCP).